GE HealthCare Technologies (GEHC) has kicked off its international Phase 2/3 LUMINA trial, dosing the first patient with mangaciclanol, a manganese based MRI contrast agent that has been granted FDA Fast Track status.

The latest product and AI partnerships are arriving at a time when momentum has softened, with a 1 day share price return of 2.81% decline, a 90 day share price return of 13.58% decline, and a 1 year total shareholder return of 0.78%. This hints that recent news is being weighed against earlier gains.

If this kind of medical imaging and healthcare AI story interests you, it could be worth broadening your watchlist with other specialised names using the 32 healthcare AI stocks.

With shares down over the last quarter despite FDA Fast Track progress and new AI partnerships, is GE HealthCare quietly trading at a discount, or is the current price already reflecting the next leg of growth?

Most Popular Narrative: 24.5% Undervalued

The most followed narrative sits on a fair value of $90.74 per share versus the latest close at $68.50, framing GE HealthCare as materially discounted in that view.

The analysts have a consensus price target of $90.74 for GE HealthCare Technologies based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $110.0, and the most bearish reporting a price target of just $75.0.

Curious what kind of revenue path and margin profile need to line up for that fair value? The narrative focuses on steady compounding and a tighter share count, which together contribute to a future earnings base and valuation multiple that carry much of the valuation argument.

Result: Fair Value of $90.74 (UNDERVALUED)

However, tariff pressure on earnings and uncertainty around China related regulations could still challenge margins and growth expectations that support this undervalued narrative.

Next Steps

Does this mix of upside potential and real concerns line up with your own view of GE HealthCare, or does it feel off? Take a closer look at the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If GE HealthCare is already on your radar, do not stop there. You can quickly scan other focused opportunities that might better fit your style and risk comfort.

• Target potential mispricings by checking out 53 high quality undervalued stocks that combine attractive prices with solid fundamentals.
• Prioritise resilience and capital strength by reviewing companies in the solid balance sheet and fundamentals stocks screener (44 results).
• Get ahead of the crowd by hunting through the screener containing 25 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.